Clinical Trial Update: Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating thrice-weekly azithromycin and rifabutin for Mycobacterium avium complex lung disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycobacterium Avium Complex Lung Disease

Drugs mentioned

• Azithromycin (azithromycin)
• RIFABUTIN (Rifabutin)

Snippet

Sponsor: The University of Texas Health Science Center at Tyler | Conditions: Mycobacterium Avium Complex | Phase 4 | Status: COMPLETED